Comparative study of the efficacy of tamoxifen and aromatase inhibitors among breast cancer patients at Kenyatta National Hospital

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study shows aromatase inhibitors improve survival and reduce disease progression in breast cancer patients.

Aromatase inhibitors showed improved outcomes, reducing mortality rates compared to tamoxifen.
Median survival time was longer for aromatase inhibitor patients at 49 months, compared to 42 months for those on tamoxifen.
Lower incidence of disease progression was observed with aromatase inhibitors at 24%, versus 29.7% with tamoxifen.
Patients receiving aromatase inhibitors had a more favorable median metastasis-free survival time of 42 months.

Macharia et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark